Merit Medical(US:MMSI) Globenewswireยท2025-09-12 18:30Core Insights - Merit Medical Systems, Inc. announced that Embosphere Microspheres are now indicated in the EU for genicular artery embolisation (GAE) to treat knee osteoarthritis (OA) [1][4] Group 1: Company Overview - Merit Medical is a global leader in healthcare technology, founded in 1987, focusing on the development, manufacture, and distribution of proprietary disposable medical devices [8] - The company employs approximately 7,300 people worldwide and serves client hospitals with a sales force and clinical support team of over 800 individuals [8] Group 2: Product and Treatment Insights - Embosphere Microspheres have been proven effective in treating knee OA, with over 75% of patients achieving clinical success and significant pain reduction sustained through 24 months [4][6] - GAE selectively reduces blood flow to the inflamed synovium, leading to meaningful reductions in knee pain and improved joint function, representing a growing trend in minimally invasive pain management therapies [3][4] Group 3: Market Context - Osteoarthritis is the most common type of arthritis, affecting approximately 595 million people globally, with knee OA being the most frequently affected joint [2] - The prevalence of OA is expected to increase due to aging populations, rising injury rates, and obesity [2] Group 4: Competitive Advantage - Embosphere's proprietary formulation and spherical shape provide complete and durable occlusion of targeted blood vessels, offering consistent and reliable performance, especially in treating small genicular arteries [5][6] - Compared to corticosteroid injections, GAE with Embosphere has shown consistently higher clinical success rates and greater improvements in pain and quality of life at three months [4]